Pharma BD Deal Intelligence

AstraZeneca PLC (Alexion) / LogicBio Therapeutics Inc.

2022 · Acquisition/Merger · $70M · Complete

Announcement Sentiment

Skeptical

Alexion (AstraZeneca Rare Disease) acquired LogicBio Therapeutics for $2.07/share (~$70M) via tender offer to gain LogicBio's GeneRide non-nuclease genome editing platform and rare-disease R&D team. Tender offer closed Nov 15, 2022; LogicBio became a wholly owned subsidiary Nov 16, 2022.

Key facts

Announced Oct 03, 2022
Closed Nov 16, 2022
Deal value $70M
Deal type Acquisition/Merger
Therapeutic area Rare genomic medicine
Indications Rare genomic medicine
Key assets Genome editing platform (GeneRide); LB-001
Mechanism Non-nuclease genome editing for in vivo gene therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals